Paradigm Biopharmaceuticals Limited (ASX:PAR) Insider Paul Rennie Buys 95,300 Shares of Stock

Paradigm Biopharmaceuticals Limited (ASX:PAR) insider Paul Rennie acquired 95,300 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The shares were purchased at an average price of A$0.21 ($0.14) per share, with a total value of A$20,108.30 ($13,405.53).

Paradigm Biopharmaceuticals Stock Performance

The company has a current ratio of 7.22, a quick ratio of 5.93 and a debt-to-equity ratio of 1.00.

About Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases.